Comparative Pharmacology
Head-to-head clinical analysis: DECABID versus LORATADINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DECABID versus LORATADINE.
DECABID vs LORATADINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Decabid is a combination of chlorpheniramine (antihistamine) and pseudoephedrine (decongestant). Chlorpheniramine competitively antagonizes histamine at H1 receptors, reducing allergic symptoms. Pseudoephedrine acts as a sympathomimetic agent, stimulating alpha-adrenergic receptors to cause vasoconstriction, reducing nasal congestion.
Loratadine is a long-acting tricyclic antihistamine with selective peripheral H1-receptor antagonist activity. It inhibits histamine-induced vasodilation and bronchoconstriction.
1 capsule orally every 12 hours; each capsule contains 10 mg phenylephrine hydrochloride and 75 mg carbinoxamine maleate.
10 mg orally once daily
None Documented
None Documented
Clinical Note
moderateLoratadine + Fluticasone propionate
"The risk or severity of adverse effects can be increased when Loratadine is combined with Fluticasone propionate."
Clinical Note
moderateLoratadine + Teriflunomide
"The metabolism of Teriflunomide can be decreased when combined with Loratadine."
Clinical Note
moderateLoratadine + Haloperidol
"The metabolism of Haloperidol can be decreased when combined with Loratadine."
Clinical Note
moderateLoratadine + Sulfisoxazole
12 hours (terminal); prolonged to 24 hours in renal impairment (CrCl <30 mL/min)
Loratadine: 8-14 hours (mean ~10 hours). Active metabolite descarboethoxyloratadine: 17-24 hours (mean ~20 hours). Clinically, duration supports once-daily dosing.
Renal (50% as unchanged drug), fecal (40% as metabolites), biliary (10% as glucuronide conjugates)
Approximately 40% excreted in urine as metabolites (primarily descarboethoxyloratadine) and 40% in feces as metabolites; <1% excreted unchanged.
Category C
Category A/B
Antihistamine/Decongestant Combination
Antihistamine
"The metabolism of Sulfisoxazole can be decreased when combined with Loratadine."